Dicot Pharma AB
Dicot Pharma AB engages in the development of pharmaceutical products in Sweden. It develops LIB-01 for the treatment of erectile dysfunction and premature ejaculation. The company was formerly known as Dicot AB (publ) and changed its name to Dicot Pharma AB in May 2024. Dicot Pharma AB was incorporated in 2015 and is based in Uppsala, Sweden.
Market Cap & Net Worth: Dicot Pharma AB (KN0)
Dicot Pharma AB (F:KN0) has a market capitalization of $80.03 Million (€77.96 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #21450 globally and #2327 in its home market, demonstrating a 78.80% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Dicot Pharma AB's stock price €0.04 by its total outstanding shares 2009342502 (2.01 Billion).
Dicot Pharma AB Market Cap History: 2026 to 2026
Dicot Pharma AB's market capitalization history from 2026 to 2026. Data shows growth from $80.03 Million to $80.03 Million (0.00% CAGR).
Dicot Pharma AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Dicot Pharma AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of KN0 by Market Capitalization
Companies near Dicot Pharma AB in the global market cap rankings as of March 19, 2026.
Key companies related to Dicot Pharma AB by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #422 globally with a market cap of $51.61 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #432 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #452 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #422 | Zoetis Inc | NYSE:ZTS | $51.61 Billion | $117.35 |
| #432 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.31 |
| #452 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Dicot Pharma AB Historical Marketcap From 2026 to 2026
Between 2026 and today, Dicot Pharma AB's market cap moved from $80.03 Million to $ 80.03 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €80.03 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Dicot Pharma AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $80.03 Million USD |
| MoneyControl | $80.03 Million USD |
| MarketWatch | $80.03 Million USD |
| marketcap.company | $80.03 Million USD |
| Reuters | $80.03 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.